Skip to content
Screener

BioCryst Pharmaceuticals BCRX Unrealized Losses on Investments (Before Tax)

Unrealized Losses on Investments (Before Tax) at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$5.01M+267%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$6K—
Amgen logo
AmgenAMGN
$0—
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
——
Precigen logo
PrecigenPGEN
——
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
——

Other financials

Income statement

See full
Revenue$218.3M+33.6%
Gross profit$214.4M+33.5%
Operating income$98.5M+231%
Net income$78.4M+1,442%
EPS (diluted)$0.30+1,400%

Balance sheet

See full
Cash & equivalents$156.4M+73.9%
Total debt$410.9M+59.9%
Total equity-$454.3M-7.8%
Total assets$557.9M+22.0%

Cash flow

See full
Operating cash flow$104.3M+153%
CapEx$209.0K+16.8%
Free cash flow$104.1M+153%

Valuation

See full
Market cap$2.51B+46.1%
Enterprise value$2.77B+46.6%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-33.3%-43.0pp
Net margin-40.9%-50.2pp
FCF margin39.7%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio2.3×+0.1×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.

The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:04 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053300
Line itemAmortized CostAccrued InterestGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
Obligations of U.S. Government and its agencies$197,381$447—$(227)$197,601
Total investments$197,381$447—$(227)$197,601

Item 1. Financial Statements (Unaudited):

FAQ

What is BioCryst Pharmaceuticals's unrealized losses on investments (before tax)?
BioCryst Pharmaceuticals (BCRX) reported unrealized losses on investments (before tax) of $227K in Q2 2026.
How has BioCryst Pharmaceuticals's unrealized losses on investments (before tax) changed year-over-year?
BioCryst Pharmaceuticals's unrealized losses on investments (before tax) increased by 1035.0% year-over-year, from $20K to $227K.
What is the long-term trend for BioCryst Pharmaceuticals's unrealized losses on investments (before tax)?
Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's unrealized losses on investments (before tax) has grown at a -83.2% compound annual growth rate (CAGR), from $1.06M to $5K.
What does unrealized losses on investments (before tax) mean?
The total unrealized losses on investments, typically related to available-for-sale securities, before considering tax effects.

Ask your AI about BioCryst Pharmaceuticals's unrealized losses on investments (before tax).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude